Mednet Logo
HomeGynecologic Oncology
Gynecologic Oncology

Gynecologic Oncology

Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.

Recent Discussions

How do positive pelvic washings influence your decision to administer adjuvant therapy to early stage endometrial cancer who otherwise meets no criteria for adjuvant therapy?

5
2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Vanderbilt University School of Medicine

<60y/o, grade 1 endometrioid endometrial cancer. TLH, BSO, sentinel nodes. Stage IA, focal LVSI, 20% myometrial invasion, negative sentinel nodes, positive pelvic washings. Positive pelvic washings are an adverse prognostic sign in patients with other high-risk features. This patient has low risk...

How does the presence of microcystic elongated and fragmented (MELF) invasion impact post operative treatment of Stage IA FIGO grade 1 endometrial cancer?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

MELF pattern may be associated with under-assessment of LVSI. In the setting of surgical assessment of nodes, we don’t change treatment recommendations just based on MELF pattern.

What is your fertility-sparing management of a stage IA1 cervical squamous cell carcinoma following a LEEP with negative margins and focal LVSI?

2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Medical University of South Carolina

The data would suggest she has been adequately treated.

If metastatic disease is found at the time of minimally invasive hysterectomy for uterine cancer, when would you decide to convert to open versus minimally invasive debulking?

2
1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Cooper Medical School of Rowan University

This depends on the extent of disease and your ability to debulk robotically. The goal should be a maximal cytoreductive effort. If that can be achieved minimally invasively, then use that approach. If not, then open.

What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?

1
2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center

Poorly controlled Hypertension Active flare of autoimmune disease On immunosuppressant therapies

What is your treatment approach for an adenoma malignum of the cervix?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Data for this rare entity is mixed but for now, treat with the same philosophy as other histology with chemo RT.

What is your preferred adjuvant treatment for surgically staged IB dedifferentiated endometrial carcinoma, with negative SLNBx and extensive LVSI?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

We would generally recommend chemotherapy at a minimum for a dedifferentiated uterine carcinoma, although approval of immunotherapy is unlikely to be obtained given IT was not studied in any stage I patients, even for high-risk histologies.As a radiation oncologist, for IB high-risk histologies case...

Do you have cut off values for neutrophil and platelet counts when doing interstitial brachytherapy for cervical cancer?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

For template-based interstitial brachytherapy, I (and my anesthesia colleagues placing the patient's epidural) require platelets > 100. I suppose for a hybrid one, could consider at 50-100 but I would still prefer > 100. > 50 is my personal threshold for ICBT alone. ANC thresholds - I'm generally ha...

How do you treat a locally advanced cervix cancer in a patient who declines brachytherapy?

4
8 Answers

Mednet Member
Mednet Member
Radiation Oncology · NYU Langone Medical Center

You provide this lady with a curable disease the appropriate social support, mental health support, and transportation coordination in order for her to complete curative treatment with brachytherapy. Anything short of that in America with all our incredible resources and care options is substandard ...

What clinical and pathological factors guide your decision making when considering whether to recommend vaginal cuff brachytherapy following TAH/BSO for a FIGO stage IA or IB endometrial carcinoma?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · St. Luke’s Cancer Center

The most important risk factors for vaginal wall recurrence for endometrioid adenocarcinomas are grade, depth of invasion and presence of lymphovascular invasion. Now that stage IA includes endometrium only and up to 50% myometrial invasion, it is important to consider the other risk factors. I usua...